@article {MIYATA4333, author = {YASUYOSHI MIYATA and MASAHITO MASATO and YUTA MUKAE and YUICHIRO NAKAMURA and TSUYOSHI MATSUDA and JUNKI HARADA and KENSUKE MITSUNARI and TOMOHIRO MATSUO and KOJIRO OHBA and HIDEKI SAKAI}, title = {Pathological Roles of Prostaglandin E2-specific E-type Prostanoid Receptors in Hormone-sensitive and Castration-resistant Prostate Cancer}, volume = {41}, number = {9}, pages = {4333--4341}, year = {2021}, doi = {10.21873/anticanres.15238}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Prostaglandin (PG) E2 mediates malignant aggressiveness by binding to four specific E-type prostanoid receptors (EP1R {\textendash} 4R). This study aimed to clarify the pathological significance of EPRs in hormone-sensitive prostate cancer (HSPC) and castration-resistant prostate cancer (CRPC). Materials and Methods: EP1R {\textendash} 4R expression was examined in 102 HSPC and 27 CRPC specimens. The relationships between their expression and proliferation index (PI), apoptotic index (AI), and vascular endothelial growth factor (VEGF)-A expression were analyzed. Results: EP4R expression in CRPC was significantly higher compared to that in HSPC, even in advanced disease (T3/4, N1, and/or M1). EP4R expression was significantly correlated with PI, AI, and VEGF-A expression in CRPC. Such significant relationships were not detected between EP1R {\textendash} 3R and CRPC. Conclusion: EP4R expression in CRPC was significantly higher than that in HSPC and was associated with cancer cell proliferation, apoptosis, and pro-angiogenetic potential.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/41/9/4333}, eprint = {https://ar.iiarjournals.org/content/41/9/4333.full.pdf}, journal = {Anticancer Research} }